These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265 [TBL] [Abstract][Full Text] [Related]
9. A narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages. Mayeli A; Clancy KJ; Sonnenschein S; Sarpal DK; Ferrarelli F Psychiatry Res; 2022 Nov; 317():114926. PubMed ID: 36932470 [TBL] [Abstract][Full Text] [Related]
10. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451 [TBL] [Abstract][Full Text] [Related]
11. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Mishara AL; Goldberg TE Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486 [TBL] [Abstract][Full Text] [Related]
12. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Allott K; Liu P; Proffitt TM; Killackey E Schizophr Res; 2011 Feb; 125(2-3):221-35. PubMed ID: 21111577 [TBL] [Abstract][Full Text] [Related]
13. [Neurocognitive insight in schizophrenia: a meta-analysis]. Potvin S; Pelletier J; Stip E Sante Ment Que; 2014; 39(2):183-200. PubMed ID: 25590551 [TBL] [Abstract][Full Text] [Related]
14. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123 [TBL] [Abstract][Full Text] [Related]
15. Cognitive training for people with mild to moderate dementia. Bahar-Fuchs A; Martyr A; Goh AM; Sabates J; Clare L Cochrane Database Syst Rev; 2019 Mar; 3(3):CD013069. PubMed ID: 30909318 [TBL] [Abstract][Full Text] [Related]
16. Antioxidant treatments for schizophrenia. Magalhães PV; Dean O; Andreazza AC; Berk M; Kapczinski F Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008919. PubMed ID: 26848926 [TBL] [Abstract][Full Text] [Related]
17. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Keefe RS; Silva SG; Perkins DO; Lieberman JA Schizophr Bull; 1999; 25(2):201-22. PubMed ID: 10416727 [TBL] [Abstract][Full Text] [Related]
18. Patient outcomes in schizophrenia II: the impact of cognition. Hofer A; Baumgartner S; Bodner T; Edlinger M; Hummer M; Kemmler G; Rettenbacher MA; Fleischhacker WW Eur Psychiatry; 2005 Aug; 20(5-6):395-402. PubMed ID: 16171654 [TBL] [Abstract][Full Text] [Related]
19. [Characteristics and impact of metacognitive deficits in schizophrenia]. Quiles C; Prouteau A; Verdoux H Encephale; 2013 Apr; 39(2):123-9. PubMed ID: 23219408 [TBL] [Abstract][Full Text] [Related]